Flavivirus immunity in endemic and non-endemic human cohorts

地方性和非地方性人群中的黄病毒免疫力

基本信息

  • 批准号:
    10561605
  • 负责人:
  • 金额:
    $ 38.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-02-16 至 2026-01-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The global spread of the arthropod borne flaviviruses dengue (DENV1-4) and Zika (ZIKV) viruses are major global public health challenges. World health organizations are calling for scientific communities to respond to this emerging threat with vaccines, therapeutics and diagnostics. However, existing gaps in fundamental knowledge about DENV and ZIKV immunity, specifically how type-specific immunity to each serotype develops and is sustained, makes rational vaccine development particularly difficult. The dominant immunity model comes from human challenge studies on DENV (1910’s-1940’s) and posits that first infection induces neutralizing antibodies that provide life-long sterilizing immunity to repeat infections by the same (homotypic) serotype virus, and this model has been extended to ZIKV without rigorous evaluation. However, recent studies from DENV endemic regions provide evidence of homotypic re-infection and natural immune boosting over time and our preliminary data from a non-endemic, Portland, Oregon resident DENV and ZIKV immune cohort show type- specific Abs decay – lose both potency and breadth - over time, calling into question sterilizing immunity and leading us to hypothesize that natural flavivirus (ZIKV and DENV) protective immunity is context dependent: in endemic transmission settings intermittent asymptomatic boosting maintains potency and breadth of virus specific immunity and in non-endemic or very low transmission settings potency and breadth of flavivirus immunity significantly wanes. To test this hypothesis, we propose to prospectively characterize and compare DENV and ZIKV immunity in a regularly re-exposed endemic cohort in Ponce, Puerto Rico with immunity in an un-boosted, non-endemic cohort of DENV immunes in Portland. This is a controversial and novel hypothesis that will call for substantial supporting evidence, hence we will compare and contrast three highly relevant and related markers of boosting between the two cohorts: The potency and breadth of neutralizing serum DENV and ZIKV specific Abs (Aim 1), the frequency of and potency of DENV and ZIKV non-structural protein 1 (NS1) specific antibodies (Aim 2), and the frequency and specificity of DENV and ZIKV specific memory B-cells (MBCs) (Aim 3). We expect to find that Abs and MBCs decline at a significantly greater rate in individuals from the non- endemic setting compared to the endemic setting supporting the hypothesis that boosting plays a critical role in natural immunity for these viruses, with implications for future vaccine development. Because MBCs are functionally linked to Abs, quantifying virus specific MBCs tests a mechanistic connection between repeat infection and Ab titer boosting. Our proposed work will comprehensively assess the role transmission context plays in flavivirus immunity using two highly relevant and mechanistically linked determinants (Ab and MBC). Irrespective of specific results, the knowledge obtained from the proposed work will be essential to DENV vaccine development and mechanistic understanding of flavivirus Ab mediated immunity.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William Messer其他文献

William Messer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William Messer', 18)}}的其他基金

Immunogenicity of the dengue vaccine CYD-TDV in a dengue virus serotype 1 immune population
登革热疫苗 CYD-TDV 在登革热病毒血清型 1 免疫群体中的免疫原性
  • 批准号:
    10728086
  • 财政年份:
    2023
  • 资助金额:
    $ 38.59万
  • 项目类别:
Flavivirus immunity in endemic and non-endemic human cohorts
地方性和非地方性人群中的黄病毒免疫力
  • 批准号:
    10353435
  • 财政年份:
    2021
  • 资助金额:
    $ 38.59万
  • 项目类别:
Flavivirus immunity in endemic and non-endemic human cohorts
地方性和非地方性人群中的黄病毒免疫力
  • 批准号:
    10211051
  • 财政年份:
    2021
  • 资助金额:
    $ 38.59万
  • 项目类别:
Long Term Immunity Following Yellow Fever Vaccination
黄热病疫苗接种后的长期免疫力
  • 批准号:
    10355419
  • 财政年份:
    2020
  • 资助金额:
    $ 38.59万
  • 项目类别:
Early and long term immunity following SARS-CoV-2 infection in humans
人类感染 SARS-CoV-2 后的早期和长期免疫力
  • 批准号:
    10493555
  • 财政年份:
    2020
  • 资助金额:
    $ 38.59万
  • 项目类别:
Early and long term immunity following SARS-CoV-2 infection in humans
人类感染 SARS-CoV-2 后的早期和长期免疫力
  • 批准号:
    10265655
  • 财政年份:
    2020
  • 资助金额:
    $ 38.59万
  • 项目类别:
Long Term Immunity Following Yellow Fever Vaccination
黄热病疫苗接种后的长期免疫力
  • 批准号:
    10558592
  • 财政年份:
    2020
  • 资助金额:
    $ 38.59万
  • 项目类别:

相似海外基金

Establishment of antibody titer measurement against Vibrio vulnificus
创伤弧菌抗体滴度测定方法的建立
  • 批准号:
    19592091
  • 财政年份:
    2007
  • 资助金额:
    $ 38.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了